| 000 | 01917 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515021731.0 | ||
| 264 | 0 | _c20060413 | |
| 008 | 200604s 0 0 eng d | ||
| 022 | _a1527-7755 | ||
| 024 | 7 |
_a10.1200/JCO.2005.03.4900 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJanmaat, Maarten L | |
| 245 | 0 | 0 |
_aPredictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cApr 2006 |
||
| 300 |
_a1612-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aClass I Phosphatidylinositol 3-Kinases |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aEsophageal Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aExtracellular Signal-Regulated MAP Kinases _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aGene Dosage |
| 650 | 0 | 4 | _aGenes, ras |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinases _xgenetics |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xmetabolism |
| 650 | 0 | 4 |
_aQuinazolines _xadverse effects |
| 700 | 1 | _aGallegos-Ruiz, Mariëlle I | |
| 700 | 1 | _aRodriguez, José A | |
| 700 | 1 | _aMeijer, Gerrit A | |
| 700 | 1 | _aVervenne, Walter L | |
| 700 | 1 | _aRichel, Dick J | |
| 700 | 1 | _aVan Groeningen, Cees | |
| 700 | 1 | _aGiaccone, Giuseppe | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 24 _gno. 10 _gp. 1612-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2005.03.4900 _zAvailable from publisher's website |
| 999 |
_c16181809 _d16181809 |
||